PAA 2.63% 19.5¢ pharmaust limited

Canine cancer treatments, page-5

  1. 15,361 Posts.
    lightbulb Created with Sketch. 584
    "PharmAust’s Executive Chairman, Dr Roger Aston said, "The veterinary applications of PPL-1, particularly for dog cancers, is under a "Research and Option Agreement" with a global company marketing animal health products. The outcome of this trial will be an important milestone for PharmAust".

    Some good news on the canine front should spark some decent interest then.
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.